Strengths, weaknesses and future challenges of biosimilars’ development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice
- 1 December 2017
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 126, 138-142
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyFrontiers in Pharmacology, 2017
- The process defines the product: what really matters in biosimilar design and production?Rheumatology, 2017
- Biosimilars in the European Union from comparability exercise to real world experience: What we achieved and what we still need to achievePharmacological Research, 2017
- Erratum to: Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literatureImmunologic Research, 2016
- Development of biosimilarsSeminars in Arthritis and Rheumatism, 2016
- Biosimilars advancements: Moving on to the futureBiotechnology Progress, 2015
- Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?The AAPS Journal, 2013
- Can HPV immunisation cause ADEM? Two case reports and literature reviewMultiple Sclerosis Journal, 2013
- Development and Regulation of Biosimilars: Current Status and Future ChallengesBioDrugs, 2013
- Immunogenicity to Biologics: Mechanisms, Prediction and ReductionArchivum Immunologiae et Therapiae Experimentalis, 2012